Jennifer Logan, MD | Authors


Promise Is Seen in Newer EGFR TKIs to Overcome Resistance in NSCLC

December 11, 2018

Acquired resistance to tyrosine kinase inhibitors targeting EGFR mutations in patients with non–small cell lung cancer are leading to next-generation therapies equipped to circumvent the mutations that arise from initial treatment. A review of these mechanisms, and the latest agents being developed to address them, shows that the pipeline holds promise for the future.